Agenda

– Introduction

– Life Science in Ireland

– Our Journey

– How we work & why investors

choose Ireland

– What next ?

– Q&A

• A third of the worlds’ contact lenses are manufactured

in Ireland

A quarter of people with Diabetes, that is 30 million people

globally, rely on an injectable device manufactured by Becton

Dickinson, Nypro and West Pharma in Ireland

• 80% of the global supply of stents are manufactured in

Ireland by Medtronic, Boston Scientific, Abbot

Vascular and others

Half of all ventilators used in acute

hospitals around the world are made in

Ireland primarily by Medtronic in Galway.

• Breakthrough breast cancer drug Tykerb was

developed and is manufactured in Ireland by

GSK.

Ireland currently produces c.10% of the entire

global exports of infant milk formula.

Allergan’s global supply

of Botox is manufactured

in Westport

Ireland experts in manufacturing

Breakthrough drugs Enbrel and Remicadeused for treating rheumatoid arthritis are made by Pfizer in Dublin and Johnson &

Johnson and Merck in Cork.

Life Sciences in Ireland

4

Companies 10 of the top 10 Pharma co’s

13 of the top 15 Medtech co’s

Exports Exports €64bn

28% of total Irish exports

Manufacturing 90 plants, 40+ FDA approved, 22

Biotech sites

Employment 60,000

Education 50% are 3rd

level graduates

25% of all PhDs in Ireland are in

industry

Compliance Unrivalled record globally

Investment €10bn in biopharma in the last decade

Training National Institute for Bioprocessing,

Research & Training (NIBRT)

5

5 operations – 1,800

people. Bulk

chemicals, Global

Business Services,

Intraocular lenses and

global Chemical HQ

6 operations – 3,000

people. Bio, API,

Global Financial

Shared Services,

5 operations – 2,600

people.

Orthopaedics,

Contact lenses, Bio,

API, Global Supply

Chain

5 operations – 1,640

people. Bio, DP, Pharma

fill-finish, R&D, Tech Ops,

Financial Shared

Services, Supply Chain

5 operations – 1,600

people. API, OTC,

Oral Care, Consumer

Products and

Commercial Ops.

6 operations – 1,700

people. API, Biologics,

R&D, EMEA Shared

Services Centre

Value Chain – our sweet spot

6

So how do we do it ?

7

The Journey

8

2005 1967

Free Hi-School

education &

setting up

Institutes of

Technology

Ireland joins

the European

Economic

Community

19871973

Third Level

Education fees

abolished for

Undergraduates

199620162012

1992: “Culliton” - focus on areas of

productivity, reduced reliance on grants

and a bringing together of multiple

factors/institutions across the economy

1992

12.5% corporate

tax rate

2000

Enterprise Ireland spun off from IDA

to increase focus on indigenous

firms

1994

2003

Single European Act

to join the Single Market

Disruptive technologies

innovation fund

20181969

Tax

The Irish tax regime is open, transparent and complies fully with OECD guidelines and EU

competition law.

– Corporation Tax – 12.5%:

applies to all Irish corporate trading profits

it is not an incentive regime, rather it is Ireland’s standard tax rate applicable to active

business or ‘trading’ income.

– R&D Tax Credit - 25%:

Qualifying R&D expenditure generates a 25% tax credit for offset against corporation tax

Qualifying expenditure includes wages, related overheads, plant and machinery, etc

– Knowledge Development Box 6.25%:

First OECD-compliant Knowledge Development Box. A tax rate of 6.25% applied to

profits from intellectual property i.e. profits from research and development

undertaken in Ireland.

9

1

0

GOAL

▪ Attracting and embedding FDI

in the Republic of Ireland

▪ 2017 turnover of €200m,

▪ Of this, €90m was given to

firms in grant funding

▪ Government agency with

considerable autonomy

▪ 22 international offices situated

across 4 continents

▪ 10 offices across the Republic

▪ Promoting the indigenous

business sector, with a

particular focus on exporting

firms

▪ 2017 turnover of around

€370m, of which €250m was

spent on financial support to

industry

▪ € 490m under management in

the seed and venture

▪ capital schemes

▪ Government agency with

▪ 31 international offices in 28

countries, with support services

provided in another 35+

countries

▪ Attracting and supporting world

class scientific researchers in

the Republic of Ireland

▪ Awarded €175m in grants in

2017

▪ Public organisation responsible

for distributing research grants

to recruit and retain research

groups

STATUS FUNDING

SOURCE: Literature review; press search; expert interviews

Key Agencies

Irish RD&I Landscape

Department of Business, Enterprise & Innovation

Supporting Research and Innovation for the Future

Supporting Indigenous Irish Companies

In-house R&D and applied Research

for MNC’s

0. Idea

1. Basic research

2. Technology formulation

3. Applied research

9. Full commercial application

RDI Funding Spectrum

SFI

4. Small scale prototype

5. Large scale prototype

6. Prototype system

7. Demonstration system

8. First of a kind commercial system

EIIDA

Variety of Supports Across Agencies

12

Financial

Supports

Capital and

Employment

Grants

(IDA)

SFI Industry Access

Innovation

Partnership

(EI)

Training

(IDA)

RDI

Programme

(IDA)

Feasibility

Programme

(IDA)

Knowledge

Development Box

6.25%

25% R&D Tax

Credit

12.5% Corporate

Tax Rate

SFI Research Centres

13

ADAPT Centre for Global Digital Content and Engagement

AMBER Advanced Materials and BioEngineering Research Centre

APC APC Microbiome Institute

CONNECT Future Broadband, Cellular and Internet of Things Networks

CÚRAM Centre for Research in Medical Devices

iCRAG Irish Centre for Research in Applied Geosciences

INFANT Irish Centre for Fetal and Neonatal Translational Research

INSIGHT Centre for Data Analytics

IPIC Irish Photonic Integration Research Centre

LERO Irish Software Research Centre

MaREI Marine and Renewable Energy Ireland

SSPC Synthesis & Solid State Pharmaceutical Centre

CONFIRM Smart Manufacturing IT and industrial automation systems

FutureNeuro Diagnosis, monitoring and treatment of neurological diseases

I-Form Innovative techniques and processes in Additive Manufacturing

BEACON Bioeconomy – extracting new value from biological wastes and residues

About IDA

Established 1969

– Government Agency (Department of Business, Enterprise & Innovation)

– Independent Board & CEO

– Overseas & Irish Offices (350 staff)

Mission:

– Attract multinational companies to invest in Ireland

– To provide jobs for the economic and social benefit of Ireland

Key sectors:

– Technology

– Consumer and Business Services

– Bio Pharmaceuticals

– Medical Devices

– Financial Services

– Engineering

14

Austin

BeijingTarget a minimum increase in investment of 30% to 40% in each region outside Dublin ……Dublin to continue to achieve the same high level of investment

How we work with companies

Evaluation & Site

Selection

Decision &

Implementation

Continuous

“After-Care”

• Organise Site-Visits to Ireland

• Provide “Due Diligence” information

• Open doors to the business community in Ireland

• Grant Aid (Regional Employment, RD&I, Training)

• Assistance with Property & Office solutions

• Press & PR

• Introductions at Government level

• Employee Work Permit / Visa support

• Influencing Government on behalf of industry

Suite of Support Services provided by IDAPhases of

Development

Galway

Dundalk

Letterkenny

Sligo

Athlone

Carrigtwohill

Ballina Cavan

College Park

Killarney

Mullagharlin SS

Cruiserath/College Park/Grange Castle SS

Greystones SS

Belview SS

Ballyadam / Carrigtwohill East SS

Ringaskiddy SS

NTP SS

Oranmore SS

Athenry SS

Raheen SS

IDA property

16

IDA

founded

State

funded

advanced

factories

built

1970’s

Private sector

built factories

for IDA

State

guaranteed 35

year lease on

buildings and

sublet them to

companies

1980’s 1995

Regional

Agenda

Land

holdings

increased in

regions

2000’s

Business and

Technology

Parks model

developed

1969

Private Sector

funded the

buildings

35 Business Parks c.1,251.0 ha

12 Strategic Sites c.942.5 ha

Total c.2,193.5 ha t

1990’s

Strategic Sites

model

developed

– 4,000 people received training in NIBRT in 2017.

– 6500m2

GMP-like facility:

Pilot scale Training and Research Facility

Upstream and Downstream Bioprocessing (Stainless Steel and Single use)

Sterile Fill finish training

Bioanalytical research & training

– NIBRT is teaming up with Philadelphia’s Thomas

Jefferson University to set up the first education and

training centre for biologics manufacturing in North

America. The collaboration is valued at about $10

million.

– Single use collaboration with GE Healthcare

18

19

Trends in BioPharmaceuticals: What Tech is

Emerging?

Niche Busters/

Molecularly Targeted

Therapeutics

Next Gen

Therapeutic

Formats

ADC’s Bispecific Ab’s Cell/Gene Therapy

Next Gen

Manufacturing

Supporting Manufacturing Evolution

– Over the next decade Pharma Manufacturing will evolve

– Embracing disruptive technologies will be required to;

• Reduce manufacturing costs

• Improve quality control

• Eliminate shortages

• Enhance compliance

• Reduce Risks

Factories of the Future:

21

Manufacturing 4.0

Additive ManufacturingCollaborative Robotics

CyberSecurity Data Analytics

IIoT

Virtual Reality

Manufacturing Informatics

22

Ireland – robust ecosystem

Last word

– “It is not the strongest of the species that survives, nor the most

intelligent that survives. It is the one that is the most adaptable

to change.”

– In the long history of humankind (and animal kind, too) those

who learned to collaborate and improvise most effectively have

prevailed.

23

24

To learn more log on to idaireland.com

+353 1 603 4000

idaireland@ida.ie

Shay Power,

IDA Ireland, Dublin

Mobile: 087 2472379

Email: shay.power@ida.ie